BIOTRONIK Revenue and Competitors

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • BIOTRONIK's estimated annual revenue is currently $1.3B per year.(i)
  • BIOTRONIK's estimated revenue per employee is $251,000

Employee Data

  • BIOTRONIK has 5197 Employees.(i)
  • BIOTRONIK grew their employee count by 2% last year.

BIOTRONIK's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
Area VPReveal Email/Phone
3
Global VP Sales - NeuromodulationReveal Email/Phone
4
Assistentin VP Corporate Tax & LegalReveal Email/Phone
5
VPReveal Email/Phone
6
CPO & VP Corporate ProcurementReveal Email/Phone
7
Area VPReveal Email/Phone
8
CIOReveal Email/Phone
9
Head Corporate Environment, Health and SafetyReveal Email/Phone
10
Head Corporate TreasuryReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$31800M1095784%$367M$146B
#2
$68.5M273N/AN/AN/A
Add Company

What Is BIOTRONIK?

BIOTRONIK is a leading medical device company that has been developing trusted and innovative cardiovascular and endovascular solutions for more than 50 years. Driven by a purpose to perfectly match technology with the human body, BIOTRONIK innovations deliver care that saves and improves the lives of millions diagnosed with heart and blood vessel diseases every year. BIOTRONIK is headquartered in Berlin, Germany, and represented in over 100 countries.

keywords:N/A

N/A

Total Funding

5197

Number of Employees

$1.3B

Revenue (est)

2%

Employee Growth %

N/A

Valuation

N/A

Accelerator

BIOTRONIK News

2022-04-20 - Remote Patient Monitoring Market Growth Prospects ...

Aerotel Medical Systems (1988) Ltd., Biotronik SE & Co. KG – themobility.club...

2022-04-20 - Intravascular Stent Market Size 2022-2030| Key Players ...

Biotronik; Boston Scientific; Cook Medical; W.L. Gore & Associates; C.R. Bard; Terumo; Abbott Laboratories; B. Braun Melsungen; Medtronic. Intravascular...

2022-04-17 - FDA approves Biotronik's programmer for implanted cardiac ...

Biotronik announced today that the FDA approved its Renamic Neo programmer for implanted cardiac rhythm management devices.

2021-07-28 - BIOTRONIK's Implantable Cardiac Monitor Receives Prestigious Industry Award

BERLIN, July 28, 2021 /PRNewswire/ -- In association with Heart Rhythm 2021, BIOTRONIK today announced that the latest implantable cardiac monitor (ICM), BIOMONITOR IIIm, has been recognized by internationally-renowned research analysts Frost & Sullivan as high-performing across a range of inn ...

2019-09-03 - ESC Congress 2019: Biotronik beats Abbott at target lesion failure

Biotronik said yesterday that its Orsiro stent tops the Xience stents made by Abbott (NYSE:ABT) when it comes to target lesion failure, according to data from a clinical trial. The randomized, controlled BioSTEMI trial was the first direct comparison between the two drug-eluting stents in patie ...